NICE to recommend Roche cancer treatment

pharmafile | June 26, 2020 | News story | Medical Communications NHS, NICE 

NICE are set to recommend Roche’s Rozlytrek (Entrectinib) cancer treatment which will be the second histology drug to be recommended for use on the Cancer Drugs Fund (CDF).

The decision is for patients over 12 years old who suffer from advanced NTRK fusion-positive solid tumours who have no satisfactory treatment options. Patients can access the treatment on the CDF when it has received marketing approval.

Karen Lightning-Jones, Head of Personalised Healthcare and Strategic Partnerships at Roche Products Limited said: “People across England will be among the first in Europe to benefit from a new generation of medicine that targets tumours based on their genetic make-up, rather than where they are in the body.

“We are proud to have worked in partnership with NHSE, NICE and the Accelerated Access Collaborative, to fast-track access. We look forward to the English Genomic Medicine Service being able to operate at full capacity and help identify those patients who may benefit from entrectinib. Our commitment is to ensure that people in the UK live longer and healthier lives, and today’s news shows how we are advancing science to achieve this.”

Between 600 to 700 people have solid tumours with NTRK gene fusions and a proportion of these people will have access to the treatment within the first year of its availability on the CDF.

Professor Peter Johnson, NHS Clinical Director for Cancer, said: “As well as helping cancer patients to continue to get essential care during the coronavirus pandemic, the NHS has been working to bring new treatments onto the frontline of patient care.

“This is the latest deal that the NHS has struck, working together with Roche, to help hundreds of cancer patients every year who will now be able to have this important molecular targeted treatment.”

Conor Kavanagh

Related Content

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the …

NICE shares draft guidance for AI’s use in radiotherapy treatment planning

The National Institute for Health and Care Excellence (NICE) has shared draft guidance surrounding nine …

Latest content